Temenos Welcomes Industry Leaders and Rising Stars of Fintech to Make Banking Better, Together at TCF Online 2021
12.5.2021 09:30:00 EEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that 10,000 business leaders and technologists will come together on 26 - 27 May at TCF Online 2021, the flagship event in banking. The two-day interactive, online-only event will feature keynotes from PayPal, Barclays and Varo, plus over 50 live and on-demand sessions and 50 industry speakers inspired by a shared mission to make banking better, together. Register for this free to attend event.
Powered by new technologies such as Cloud, AI and SaaS, banks of all sizes can deliver customer experiences that are better, faster and smarter. They can also achieve hyper-efficient cost models to deliver more value to their customers and leverage open ecosystems to enhance and extend their offering. At TCF Online 2021, Temenos will unveil game-changing innovations enabling banks to simplify their operations, innovate and collaborate at speed and digitally transform faster than ever before.
At TCF Online 2021, attendees from over 150 countries will also hear from some of the most influential industry experts in the financial sector, including:
- Ryan Prichard, VP, CTO of Global Credit, PayPal, on the latest innovations in payments, including how PayPal is disrupting the market with its new buy now, pay later product enabled by Temenos technology.
- Ashok Vaswani, CEO of Consumer Banking and Payments, Barclays, on the importance of banks being purpose-led and playing a greater role in the economy and society in a post-pandemic world.
- Colin Walsh, Founder and CEO, Varo, a year on after making history as the first fintech in the U.S. to obtain a national banking license, on making banking more accessible and inclusive for all.
- Jim Marous, co-publisher of The Financial Brand and top 100 influencer, on how banks can humanize their customer experience in a digital world and joining him on the virtual stage, Chris Parker, Co-CEO of Partners Federal Credit Union.
- Eric Purdum, General Manager, DXC on its collaboration with Temenos and accelerating the digital transformation for large tier-1 banks.
- David Hornery, Co-CEO and Co-Founder, Judo, on the future for challenger banks and Judo’s unique approach to the SME market in Australia.
- Barri Maggott, CEO, Curo Fund Services, on the digital transformation journey in funds administration.
- And Max Chuard, CEO of Temenos, on the once-in-a-generation opportunity digital presents for banking, unveiling Temenos’ latest innovations in cloud and AI that will propel the industry forward.
Max Chuard, CEO, Temenos, said: “The urgency for change in banking has never been greater. Consumers and business customers demand and expect fast, frictionless, personalized experiences. Covid-19 has accelerated the trend towards digital banking and new technologies such as Cloud, AI and SaaS make the business case for transformation compelling. Yet while challengers are innovating and launching rapidly on modern technology stacks, legacy systems are still holding banks back. Temenos technology gives all banks the freedom, agility and speed to innovate and adapt to changing customer behavior, business and regulatory change. At TCF Online 2021, our community of thousands will hear about the latest innovations and how together we will make banking better.”
TCF Online brings the key announcements, customer insights and latest software demonstrations from Temenos. To register for this free-to-attend event, visit www.temenos.com/events/tcf-online-2021.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005935/en/
Contact information
Media Contacts
Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Email : press@temenos.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom